Lava Therapeutics Nv ( (LVTX) ) has released its Q4 earnings. Here is a breakdown of the information Lava Therapeutics Nv presented to its investors.
Lava Therapeutics N.V. is a clinical-stage immuno-oncology company specializing in the development of bispecific gamma delta T cell engagers for the treatment of solid tumors and hematologic malignancies. In its latest earnings report, Lava Therapeutics announced a focus on evaluating strategic alternatives and a restructuring plan to extend capital resources, which included a 30% reduction in workforce. The company highlighted ongoing Phase 1 enrollment for its LA V A-1266 clinical trial and achieved a $5 million development milestone from Johnson & Johnson. Lava Therapeutics reported a cash balance of $76.6 million as of December 31, 2024, expected to fund operations into 2027. The company saw an increase in revenue to $12 million for the year ended December 31, 2024, primarily due to milestones achieved with Pfizer and Johnson & Johnson. Despite a net loss of $25.1 million for the year, this was an improvement from the previous year’s loss of $41.9 million. Looking ahead, Lava Therapeutics aims to maximize shareholder value by exploring strategic options while continuing its clinical trials and partnerships.